Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide; valsartan -

Велика Британія - англійська - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - tablets - 80mg/400mg - combinations of sulfonamides and trimethoprim, incl. derivatives - it indicated for: treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infection; acute otitis media; acute exacerbation of chronic bronchitis

Велика Британія - англійська - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - tablets - 800mg/160mg - combinations of sulfonamides and trimethoprim, incl. derivatives - it is indicated for: treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infection; acute otitis media; acute exacerbation of chronic bronchitis

Велика Британія - англійська - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - suspension - 80mg/400 mg per 5 ml - combinations of sulfonamides and trimethoprim, incl. derivatives - it is indicated for: treatment and prevention of pneumocystis jiroveci.(p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infections; acute otitis media; acute exacerbation of chronic bronchitis

Філіппіни - англійська - FDA (Food And Drug Administration)

metz pharma'l inc - co-amoxiclav - powder for oral suspension - 400mg + 57mg per 5ml

Філіппіни - англійська - FDA (Food And Drug Administration)

metz pharma'l inc - co-amoxiclav - powder for oral suspension - 200mg + 28.5mg per 5ml

Філіппіни - англійська - FDA (Food And Drug Administration)

the generics pharmacy, inc - co-amoxiclav - powder for suspension - 400 mg/57 ml

Європейський Союз - англійська - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

США - англійська - NLM (National Library of Medicine)

aurobindo pharma limited - zaleplon (unii: s62u433rmh) (zaleplon - unii:s62u433rmh) - zaleplon 5 mg - zaleplon capsules are indicated for the short-term treatment of insomnia. zaleplon capsules have been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see clinical trials  under clinical pharmacology ). they have not been shown to increase total sleep time or decrease the number of awakenings. the clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. the final formal assessments of sleep latency were performed at the end of treatment. zaleplon capsules are contraindicated in patients: - who have experienced complex sleep behaviors after taking zaleplon capsules (see warnings ). - with hypersensitivity to zaleplon or any excipients in the formulation (see precautions ). zaleplon is classified as a schedule iv controlled substance by federal regulation.  abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

averroes pharmaceuticals sdn. bhd. - potassium clavulanate; amoxicillin sodium -